What is a typical sermorelin dose?

There is no single established adult dose. Published protocols ranged from 30 mcg/kg at bedtime in children with diagnosed GH deficiency to 2 mg nightly in a six-week study of 11 older men, while another adult study used a modified analogue rather than sermorelin. A prescriber sets the actual amount for the individual and the dispensed concentration.

Why is sermorelin commonly dosed at night?

Night timing is intended to align the GHRH signal with normal pulsatile growth-hormone physiology. In adults, the most prominent GH pulse commonly follows sleep onset and overlaps with deep sleep. That makes the person's habitual sleep period more relevant than a universal clock time, although the rationale does not prove that one nightly schedule is optimal for every adult.

Is sermorelin dosing based on body weight?

It can be, but not every adult prescription follows a simple weight formula. Historical pediatric studies used micrograms per kilogram, and one study of a modified GHRH analogue in older adults did as well. A current prescriber may also consider age, pituitary reserve, clinical purpose, IGF-1 trends, tolerability and the pharmacy's exact formulation before setting or changing the dose.

How is a sermorelin dose monitored?

Monitoring is individualized and may include symptoms, adverse effects and IGF-1 when clinically relevant. A random growth-hormone level is difficult to interpret because GH is released in pulses and a single sample may catch a peak or a trough. The prescriber decides which follow-up measures matter and whether the amount should stay the same, change or stop.

Are syringe units the same as a sermorelin dose?

No. Micrograms describe the amount of sermorelin, while syringe units describe a volume of liquid. If the concentration in the vial changes, the same volume can contain a different number of micrograms. That is why the dose, concentration and labeled volume form one prescription-specific calculation rather than three interchangeable numbers.

Is Promise's compounded sermorelin FDA-approved?

No. The compounded sermorelin formulation offered through Promise is not FDA-approved. Earlier Geref products had approved pediatric and diagnostic uses, but those approvals were withdrawn in 2009; FDA later determined the withdrawals were not for safety or effectiveness reasons. That history does not make a current compounded formulation an approved product.

Sermorelin Dosing: How Prescribers Set a Dose

Sermorelin dosing has no single established adult standard. A prescriber chooses the amount, timing and pace of titration from the reason it is being considered, body size, pituitary function, laboratory trends, tolerability and the exact concentration dispensed. Nighttime is common because sermorelin is a GHRH analogue: it signals the pituitary to release the body's own growth hormone, which normally arrives in pulses rather than at a steady rate.

The numbers in older studies are useful context. They are not a schedule for self-administration, and pediatric protocols cannot be carried into adult compounded care.

Why sermorelin is usually dosed at night

The sleep story is about physiology, not a magic hour on the clock. In a classic study of eight young adults across 38 nights, the major growth-hormone peak appeared with the onset of deep sleep and lasted 1.5 to 3.5 hours. When sleep was delayed, the peak moved with it (Takahashi et al., J Clin Invest 1968).

That pattern gives bedtime dosing its rationale. A short-acting GHRH signal near sleep onset may line up with the period when the hypothalamus and pituitary usually generate their largest GH pulse. It also helps explain why the relevant timing is often a person's habitual sleep period, not simply 9 p.m. for everyone. Shift work, irregular sleep and travel can therefore matter to the prescriber's decision.

The rationale should not be mistaken for proof that one nightly injection is optimal for every adult. GH pulses also occur outside deep sleep, and the size of the response varies with age, body composition, pituitary reserve and other biology. Sermorelin also differs from injecting growth hormone directly; sermorelin versus HGH explains that distinction.

What published sermorelin dosing protocols used

Published protocols span different ages, diagnoses, molecules and delivery patterns. The table preserves those differences because collapsing them into one “usual dose” would be misleading.

Published evidence	Population and duration	Amount and timing studied	What it does not establish
Thorner et al., JCEM 1996	110 prepubertal children with GH deficiency; up to 1 year	GHRH(1–29) 30 mcg/kg subcutaneously once daily at bedtime	An adult wellness dose; 86 children were eligible for efficacy analysis and this was an open-label pediatric study
Chen et al., Acta Paediatr 1993	60 children with hypothalamic GH deficiency; 6 months	GHRH(1–29)-NH2 30 or 60 mcg/kg/day by continuous infusion	A bedtime injection schedule; the route and clinical population were different
Vittone et al., Metabolism 1997	11 healthy men ages 64–76 with low baseline IGF-I; 6 weeks	GHRH(1–29) 2 mg subcutaneously nightly	A general adult standard; the investigators called the single-nightly approach less effective than multiple daily dosing for GH- or IGF-I-mediated effects
Khorram et al., JCEM 1997	19 adults ages 55–71; 4 weeks of placebo then 16 weeks active	10 mcg/kg nightly at 9 p.m.	A sermorelin protocol; the compound was modified [Nle27]GHRH(1–29)-NH2, a close analogue rather than sermorelin itself

This is why a study number is not a titration ladder. The 30 mcg/kg bedtime regimen came from children with diagnosed GH deficiency. The 2 mg nightly study involved only 11 older men and lasted six weeks. The weight-based 10 mcg/kg study used a modified molecule. Each answers a narrow research question; none creates a current, broadly accepted adult regimen.

How a prescriber individualizes sermorelin dosing

A dosing decision usually brings several variables together:

Clinical purpose and evidence boundary. A provider first decides whether the request is medically coherent and whether sermorelin's pituitary-dependent mechanism fits it. An adult compounded prescription is not the same clinical situation as treatment of pediatric GH deficiency in the 1990s.
Pituitary reserve. Sermorelin can only prompt cells in the anterior pituitary that are capable of responding. A history involving the pituitary, hypothalamus, brain radiation or surgery changes the question before a dose is discussed.
Age, body size and baseline markers. Some published protocols were weight-based, but that does not make every current adult prescription a simple micrograms-per-kilogram calculation. IGF-1 can provide a steadier view of the GH axis than a random GH value, which may catch either a pulse or a trough.
Response and tolerability. Follow-up may lead the prescriber to maintain, lower, raise or stop the prescribed amount. Injection-site reactions, flushing, headache, swelling, glucose-related concerns and other changes belong in that review; sermorelin side effects covers the safety conversation in more detail.
The dispensed concentration. Micrograms state the drug amount. Syringe “units” state a volume. The same number of units can represent a different dose when the vial concentration changes, so the prescription and pharmacy label have to be read as one set of information.

This is titration in its proper sense: a clinician interpreting a response over time, not a fixed escalation copied from a study.

What compounded status changes

Promise's sermorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The regulatory history can sound contradictory unless the dates stay attached. Geref products were once approved for a pediatric indication and a diagnostic use; their approvals were withdrawn effective June 18, 2009. In a March 4, 2013 FDA determination, the agency said they had not been withdrawn for reasons of safety or effectiveness. That finding did not restore the discontinued products or approve today's compounded formulations.

Regulatory status is one input into care, not a substitute for clinical judgment. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, sets the actual dose and either prescribes or declines based on medical eligibility. Not everyone qualifies.

What follow-up can change

A prescriber may compare baseline and follow-up information, including IGF-1 when clinically relevant, with the reason treatment was considered and any adverse effects. A number outside the intended range, little meaningful response, a new medication or a change in health can all alter the plan. Because a random GH measurement is difficult to interpret against a pulsatile background, it is not a simple dose gauge by itself.

Timing can change too. The physiologic argument is alignment with sleep onset, so an unusual sleep schedule deserves more thought than a generic instruction to dose “at night.” The pharmacy's labeled storage, preparation and administration directions remain formulation-specific. Broader outcome claims should be kept separate from dosing mechanics; the evidence behind common claims is reviewed in sermorelin benefits.

The questions a dosing plan should answer

A complete prescription makes the drug amount in micrograms, the vial concentration and the corresponding volume unambiguous. It also defines the timing relative to the person's sleep period, what follow-up information the provider expects, which effects warrant contact and how missed or delayed doses are handled. Those details can differ even when two prescriptions contain the same peptide.

The short answer is therefore precise: night dosing follows the normal pulsatile-GH story, while the dose itself comes from an individualized medical decision. Published amounts show what researchers tested in defined populations. They do not replace the prescription written for one patient and one compounded formulation.